CLOSED
NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%
INInvesco MFDirect · Growth

Invesco India Pharma and Healthcare Fund - Growth - Direct Plan

Pharma & Health CareEquity - Sectoral Fund - Pharma & Health CareBenchmark: BSE Health Care - TRI
NAV · 15 Sep 2026₹9.90-0.90%
AUM—
Expense Ratio—
CAGR—
Exit Load0.50% on or before 3M, NIL after 3M
Min SIP₹100from this fund's primary plan
Launched2026

Investment Objective

To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors. There is no assurance that the investment objective of the Scheme will be achieved.

Fund Mandate

Debt and Money Market Instruments0%–20%
Equity & Equity related instruments of companies in the Pharma, Healthcare & allied sectors80%–100%
Money Market / Other Liquid Instruments0%–20%
Other equity and equity related instruments0%–20%
Units issued by InvITs0%–10%
Fund Managers
AK
Aditya Khemani
Fund Manager
Key Information
—
₹100from this fund's primary plan
₹1,000
0.50% on or before 3M, NIL after 3M
Nil
Inception07 Sep 2026
AMCInvesco MF
Top Holdings

Portfolio holdings not disclosed for this fund yet.

On This Page
NAV growthTop holdings
Similar Funds
TRUSTMF Small Cap Fund - Growth - Direct PlanTrust MF+28.42%TRUSTMF Small Cap Fund - IDCW - Direct PlanTrust MF+28.42%Kotak Healthcare Fund - Growth - Direct PlanKotak MF+26.51%Kotak Healthcare Fund - IDCW - Direct PlanKotak MF+26.50%Kotak Healthcare Fund - IDCW Payout - Direct PlanKotak MF+26.50%
Compare With

TRUSTMF Small Cap Fund - Growth - Direct Plan and 4 more peers in this category.

Build comparison
Trailing Returns
PeriodReturnsCategory avg
1 Day-0.90%—
1 Week-1.00%-2.62%
-1.00%+16.23%

Category avg is the average return of every scheme in this fund's SEBI class (Equity - Sectoral Fund - Pharma & Health Care) over the same period. Returns up to 1 year are absolute; returns beyond 1 year are annualised (CAGR). This is Accord's own stated convention for equity-oriented schemes.

Risk Metrics

Risk metrics are not available for this fund.

Fees
—
0.50% on or before 3M, NIL after 3M
Nil
₹100from this fund's primary plan
₹1,000
Capital Gains Tax, general rules

This is an equity-oriented fund. Under rules effective since Budget 2024 (23 July 2024):

Short-Term Capital Gains (held ≤ 12 months): taxed at a flat 20%.

Long-Term Capital Gains (held > 12 months): taxed at 12.5% on gains above ₹1.25 lakh in a financial year, with no indexation benefit.

General information only, not tax advice, actual liability depends on your overall income and applicable law at the time of redemption. Consult a tax advisor for your specific situation.

Frequently Asked QuestionsGeneral mutual-fund FAQs, not specific to this scheme